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Abstract
This study demonstrates that IL-23 stimulates the differentiation
of human osteoclasts from peripheral blood mononuclear cells
(PBMC). Furthermore, in vivo blockade of endogenous IL-23
activity by treatment with anti-IL-23 antibody attenuates
collagen-induced arthritis in rats by preventing both
inflammation and bone destruction. IL-23 induced human
osteoclastogenesis in cultures of PBMC in the absence of
osteoblasts or exogenous soluble-receptor activator of NF-
kappaB ligand (RANKL). This IL-23-induced osteoclastogenesis
was inhibited by osteoprotegerin, anti-IL-17 antibody, and
etanercept, suggesting that RANKL, IL-17, and TNF-alpha are
involved. In addition, we found the ratio of production levels of
IL-17 to those of IFN-gamma from activated human T cells was
elevated at 1 to 10 ng/ml IL-23. The inductive effect of IL-17 and
the inhibitory effect of IFN-gamma on osteoclastogenesis
indicate that the balance of these two cytokines is particularly
important. We also demonstrated that IL-23 administered at a
later stage significantly reduced paw volume in rats with
collagen-induced arthritis, in a dose-dependent manner.
Furthermore, anti-IL-23 antibody reduced synovial tissue
inflammation and bone destruction in these rats. These findings
suggest that IL-23 is important in human osteoclastogenesis
and that neutralizing IL-23 after onset of collagen-induced
arthritis has therapeutic potential. Thus, controlling IL-23
production and function could be a strategy for preventing
inflammation and bone destruction in patients with rheumatoid
arthritis.
Introduction
Rheumatoid arthritis is a chronic inflammatory disease charac-
terized by the destruction of articular cartilage and bone [1].
Our group and another have detected osteoclasts in synovial
tissues [2] and eroded bone surfaces [3], suggesting that
osteoclastic bone resorption is involved in the pathogenesis of
rheumatoid arthritis (RA).
Furthermore, levels of inflammatory cytokines such as TNF-α,
IL-6, and IL-1 are elevated in synovial fluids of patients with RA
[4,5], and the cytokines promote bone resorption by inducing
the differentiation or activation of osteoclasts [2,6,7]. It is well
known that attenuating the activity of inflammatory cytokines in
patients with RA inhibits bone resorption and destruction.
IL-23, which was recently identified as a heterodimeric, proin-
flammatory cytokine and new member of the IL-12 family [8],
is secreted by antigen-presenting cells. IL-23 is composed of
p19 and p40 subunits and shares a common p40 subunit with
IL-12 [8]. IL-23 signals through the IL-23 receptor complex,
which is composed of the IL-12 receptor β chain and the IL-23
receptor [9]. IL-23 was initially described as a cytokine able to
induce the expression of IFN-γ in human CD45RO-positive
(memory) T cells and to activate memory T cells to secrete
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thermore, it is reported that recombinant human (rh)IL-23
upregulates the production of IFN-γ, IL-17, and IL-10 in acti-
vated human naïve T cells [11]. In models of T helper type 1
(Th1) differentiation of human T cells, it was initially proposed
that IL-23 acts later than IL-12 and maintains Th1 commitment
by its preferential action on memory T cells [12-14].
In animal studies, it is reported that IL-23-deficient (IL-23
p19-/-) mice are resistant to experimental autoimmune
encephalomyelitis (EAE), whereas IL-12 (p35)-deficient mice
are still susceptible to inflammation [15]. Murphy and col-
leagues reported that mice with collagen-induced arthritis
(CIA) and IL-23 deficiency (IL-23 p19-/-) are completely resist-
ant to the development of joint and bone pathology and that IL-
23 is required for the induction of joint inflammatory mediators
including IL-17 and TNF-α [16]. Furthermore, transgenic mice
constitutively overexpressing IL-23 p19 develop spontaneous
severe multi-organ inflammation with elevated levels of TNF-α
[17]. These findings suggest that IL-23 has a pivotal role in the
establishment and maintenance of inflammatory autoimmune
diseases. In addition, some reports have established the idea
of a critical function for the IL-23–IL-17 pathway in some
autoimmune diseases and emphasize the importance of
understanding the origins of development of IL-17 effector
cells [10,18].
IL-17 is a proinflammatory cytokine secreted by activated T
cells [19] or neutrophils [20]. We have reported that IL-17 lev-
els in synovial fluids are significantly higher in patients with RA
than in patients with osteoarthritis and that IL-17 stimulates
osteoclast differentiation by inducing the expression of recep-
tor activator of NF-κB ligand (RANKL) via a mechanism involv-
ing the synthesis of prostaglandin E2 in osteoblasts in vitro
[21]. In addition, we reported that IL-17 directly stimulates
human osteoclastogenesis from human monocytes alone, via
the TNF-α or RANK–RANKL pathway [22]. Recently, some
groups have reported that IL-17 is also important in joint
destruction in animal models and in patients with RA [23-25].
It is therefore indicated that IL-23 is involved in osteoclastic
bone resorption, at least in part via the IL-17 pathway, and that
IL-23 is important in the progression of arthritis. However, the
direct effect of IL-23 on human osteoclastogenesis from
peripheral blood mononuclear cells (PBMC) and the role of
anti-IL-23 antibody in CIA in rats remain unclear.
In the present study we examined the direct role of IL-23 in
osteoclastogenesis by using cultures of human PBMC. Fur-
thermore, to clarify the role of IL-23 antibody in the later stage
of CIA, rats with CIA were treated with anti-IL-23 antibody at a
later stage after the onset of clinical arthritis.
Materials and methods
Reagents
rhIL-23 and anti-IL-17 antibody were purchased from R&D
Systems Inc. (Minneapolis, MN, USA). Goat polyclonal anti-IL-
23 antibody was purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Recombinant human macrophage-
colony stimulating factor (M-CSF; Leukoprol) was obtained
from Yoshitomi Pharmaceutical (Osaka, Japan). Recombinant
human soluble RANKL (sRANKL) was obtained from Pepro-
Tech (London, UK). Microbeads for immunopurification were
obtained from Miltenyi Biotec (Auburn, CA, USA). Anti-human
CD51/61 mAb was purchased from BD Bioscience Pharmin-
gen (San Diego, CA, USA). Osteoprotegerin (OPG) was a gift
from Sankyo Pharmaceutical (Tokyo, Japan), and etanercept
was purchased from Takeda Pharmaceutical (Tokyo, Japan).
Culture system for osteoclastogenesis in the absence of 
osteoblasts
Human peripheral blood was obtained from the buffy coat frac-
tion from healthy volunteers (Japanese Red Cross Society,
Tokyo, Japan) after this study had been approved by the Insti-
tutional Review Board. PBMC were isolated by centrifugation
over Histopaque 1077 (Sigma, St Louis, MO, USA) density
gradients, washed, and resuspended at 1.3 × 106 cells/ml in
α-MEM (Gibco BRL, Gaithersburg, MD, USA) supplemented
with 10% fetal bovine serum (JRH Biosciences, Lenexa, KS,
USA). PBMC were cultured for 3 days in 48-well plates (5 ×
105 cells/0.3 ml per well; Corning, NY, USA) in the presence
of M-CSF (100 ng/ml) and various concentrations of rhIL-23
(R&D Systems Inc., Minneapolis, MN, USA). In some experi-
ments, we simultaneously added OPG (250 ng/ml), etaner-
cept (0.01 μg/ml), or anti-IL-17 antibody (5 μg/ml). Adherent
PBMC were used as monocytes in the culture system. After
non-adherent cells had been removed, adherent PBMC, as
described above, were cultured in the presence of M-CSF for
7 days. Culture medium was replaced every 3 days with fresh
medium supplemented with the agents described above.
Osteoclast formation was evaluated by immunohistochemical
staining for vitronectin receptors after 7-day culture. As a neg-
ative control, human PBMC were cultured for the first 3 days
in the presence of M-CSF and then adherent cells were further
cultured with M-CSF alone for 7 days. As a positive control,
human PBMC were cultured for the first 3 days in the pres-
ence of M-CSF and then adherent cells were further cultured
with M-CSF and sRANKL (100 ng/ml) for 7 days.
Determination of osteoclast characteristics
Adherent cells were fixed and stained for vitronectin receptor
[26]. For immunohistochemical staining, adherent cells cul-
tured for 7 days were fixed with cold methanol/acetone
(50:50, v/v) for 10 minutes. Samples were then incubated with
monoclonal antibodies against vitronectin receptor αvβ3
(CD51/61). Bound antibodies were revealed with biotinylated
secondary antibodies, avidin–biotin-conjugated peroxidase,
and a diaminobenzidine substrate kit (Histofine; Nichirei Co.,Page 2 of 12
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activity was detected as described previously [21]. Pit forma-
tion assay was performed with Osteologic® (BD Biosciences,
San Jose, CA, USA). Phagocytosing activity was detected by
phagocytes of fluoresbrite YG microspheres® (Poly Sciences,
Inc., Warrington, PA, USA).
IL-17 and IFN-γ measurement from human T cells 
stimulated by IL-23
Human CD3-positive T cells were separated from PBMC
obtained from the same volunteers by magnetic cell sorting
(Miltenyi Biotec, Sunnyvale, CA, USA) and cultured in 96-well
plates (105 cells/0.2 ml per well; Iwaki, Tokyo, Japan)
containing α-MEM supplemented with 10% fetal bovine
serum. We verified that CD3-positive T cells were purified to
98% after magnetic cell sorting. Plates were coated overnight
with anti-CD3 mAb (0.1 μg/ml; Beckman Coulter, Fullerton,
CA, USA) and then washed; anti-CD28 mAb (2 μg/ml; Beck-
man Coulter) was then added to each well. At the beginning
of cell culture, rhIL-23 was added at 1, 3, or 10 ng/ml. After 48
hours, supernatants were collected to determine cytokine lev-
els. Amounts of IL-17 and IFN-γ in the supernatants were
measured with ELISA kits (R&D Systems Inc., Minneapolis,
MN, USA) in accordance with the manufacturer's instructions.
Animals
A total of 28 seven-week-old female DA/Slc rats (Nihon SLC,
Hamamatsu, Japan) were housed in a temperature-controlled
room (21 to 26°C) with a 12-hour alternating light/dark cycle.
Animals were given rat chow (Oriental Kobo, Tokyo, Japan)
and water ad libitum before and throughout the experiments.
Animal studies were approved by the Institutional Review
Board.
Induction of collagen-induced arthritis
Animals were handled 2 weeks before experiments and every
2 to 3 days throughout the study. Food and fluid intake as well
as body weight were monitored. Arthritis was induced by
immunizing with type II collagen (CII; Anthrogen-CIA™Colla-
gen; Chondrex, LLC, Redmond, WA, USA). Dissolved CII
(0.3%, 2 ml) was emulsified with 3 ml of Freund's incomplete
adjuvant and 1 ml of saline. The final concentration of CII was
1 mg/ml. Rats were immunized intradermally in the tail with
200 μl of emulsion on days 0 and 7 [27]. Onset of arthritis usu-
ally occurred during the window of days 12 to 14. Treatment
with anti-IL-23 antibody was initiated on day 14, 10 days after
the first clear onset of clinical signs of arthritis as demon-
strated by ankle joint swelling.
Experimental protocol
Arthritis was induced in 16 female DA/Slc rats, which received
3 μg ('low') or 6 μg ('high') anti-IL-23 antibody (Santa Cruz
Biotechnology) intraperitoneally on alternate days from day 14
(later stage, after CIA onset) up to day 23. Eight other rats
received an equal volume of sterile phosphate-buffered saline.
Arthritis was not induced in four female DA/Slc rats, acting as
normal controls. A total of 28 rats were killed on day 28.
Assessment of arthritic damage
Disease progression was monitored from the induction of
arthritis (day 0) until day 28, when the rats were killed with
intraperitoneal pentobarbital. Four indices of arthritis activity
were used, and joint swelling in both ankles was measured
every 3 to 4 days by plethysmometry (TK101CMP;
Muromachi-kikai, Tokyo, Japan). Arthritis score was measured
every 3 to 4 days by inflammation of paws (0, normal; 1, mild
swelling and erythema of digits or ankles; 2, moderate swelling
and erythema of digits or ankles; 3, marked swelling of paws
including digits; 4, severe swelling and erythema with limited
motion in many joints). Rats were killed on day 28, and both
ankles were removed for histologic and radiographic examina-
tion to assess joint damage. Radiographic examination was
performed in all rats. After radiography, paraffin sections were
prepared for histological analysis.
Statistical analysis
Data were analyzed with the Mann–Whitney U test, Student's
t test, and Welch's t test (Stat View®; Abacus Concepts, Ber-
keley, CA, USA). P values less than 0.01 or 0.05 were consid-
ered significant. All values are represented as means and SD.
Results
IL-23 directly induces osteoclastogenesis from human 
PBMC
To investigate whether rhIL-23 induces osteoclastogenesis,
human PBMC were cultured with M-CSF and rhIL-23 for 3
days; after non-adherent cells had been removed, adherent
cells were cultured with M-CSF alone for 7 days. Compared
with a negative control (Figure 1a) and a positive control (Fig-
ure 1b) stained for TRAP, multinuclear cells formed by rhIL-23
and M-CSF showed TRAP activity (Figure 1c), CD51 expres-
sion (Figure 1d), and the ability to form resorption pits on
Osteologic® (Figure 1e). The multinuclear cells therefore
showed the functions and properties of authentic osteoclasts.
Stimulation with rhIL-23 for 3 days increased the number of vit-
ronectin receptor (CD51)-positive multinuclear cells. As
shown in Figure 2, rhIL-23 increased the number of CD51-
positive osteoclasts in a dose-dependent manner even in the
absence of osteoblasts or exogenous sRANKL. The effect of
osteoclastogenesis induced by IL-23 was maximal at 1.0
ng/ml rhIL-23 (Figure 3). In contrast, rhIL-23 did not induce
osteoclastogenesis in a culture of human monocytes alone
(data not shown). These findings suggested that T cells were
required for IL-23-induced human osteoclastogenesis from
PBMC.
IL-23-induced osteoclastogenesis is inhibited by OPG, 
anti-IL-17 antibody and etanercept
To investigate factors influencing IL-23-induced osteoclas-
togenesis, we used OPG, anti-IL-17 antibody, or etanerceptPage 3 of 12
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Formation of human osteoclasts from PBMC induced by rhIL-23 (1.0 ng/ml) and M-CSF. As negative and positive controls, peripheral blood mono-
nuclear cells (PBMC) were cultured with macrophage-colony stimulating factor (M-CSF) alone during the first 3 days; as a negative control, adher-
ent cells were then cultured with only M-CSF (a), and as a positive control they were cultured with M-CSF plus soluble receptor activator of NF-κB 
ligand (sRANKL; 100 ng/ml) (b) for the last 7 days. Human osteoclasts induced from PBMC by recombinant human (rh)IL-23 (1.0 ng/ml) and M-
CSF were detected by staining with tartrate-resistant acid phosphatase (TRAP) (c) and immunohistological staining by vitronectin receptor αvβ3 
(CD51/61) (d). (e) Osteoclasts induced from PBMC by rhIL-23 (1.0 ng/ml) were also evaluated functionally by pit formation on Osteologic®. Origi-
nal magnification ×100.
Figure 2
IL-23-induced formation of human osteoclasts from peripheral blood mononuclear cells (PBMC). PBMC were cultured in the presence of macro-
phage-colony stimulating factor (M-CSF) and recombinant human (rh)IL-23 (0.01, 0.1, 1.0, 10, 100, or 200 ng/ml) during the first 3 days. Adherent 
cells were then cultured with M-CSF alone during the last 7 days (days 4 to 10 (a–g) as indicated). Original magnification ×100.Page 4 of 12
(page number not for citation purposes)
Available online http://arthritis-research.com/content/9/5/R96as a TNF-α inhibitor with rhIL-23 (1.0 ng/ml) in cultured
PBMC. As shown in Figure 4, IL-23-induced osteoclastogen-
esis was inhibited by OPG (Figure 4d), anti-IL-17 antibody
(Figure 4e), and etanercept (Figure 4f). These findings sug-
gested that IL-23 induced osteoclastogenesis via a pathway
including RANK–RANKL, IL-17, and TNF-α.
The ratio of production levels of IL-17 to those of IFN-γ 
from activated human T cells by IL-23 is dose-
dependently elevated without significant changes in IL-
17 production
To clarify the pathways underlying IL-23-induced osteoclas-
togenesis, we investigated proinflammatory cytokine
production by human T cells stimulated by IL-23. As shown in
Figure 5a, IL-23 induced IL-17 production in human non–acti-
vated T cells in a dose-dependent manner; however, there
were no significant changes among different IL-17 levels. IL-
23 also induced IL-17 production in human activated T cells,
and the levels of IL-17 secreted by activated T cells were sig-
nificantly higher than those secreted by non–activated T cells
(Figure 5b). However, levels of IL-17 secreted by activated T
cells were not significantly changed by stimulation with IL-23
(Figure 5b). As well as the production of IL-17, IL-23 also
induced that of IFN-γ by activated human T cells, and the levels
of IFN-γ secreted by activated T cells were significantly higher
than those secreted by non–activated T cells; however, the
levels of IFN-γ secreted by activated T cells were not signifi-
cantly changed by stimulation with IL-23 (Figure 5c). The ratio
of production levels of IL-17 to levels of IFN-γ peaked at 10
ng/ml IL-23 (Figure 5d).
Time course of collagen-induced arthritis
Figure 6a–c shows the paws of rats on day 28. Joint swelling
in paws increased more in affected rats treated with vehicle
than in controls (Figure 6a,b). Joint swelling in paws was
reduced by IL-23 blockade in rats treated from day 14 (Figure
6b,c). Synovial tissues obtained on day 28 were stained with
hematoxylin and eosin; active synovitis and bone erosion were
detected in specimens from arthritic paws treated with vehicle
(Figure 6e) but not in specimens from paws from controls (Fig-
ure 6d). The 3.0 μg dosage of anti-IL-23 antibody reduced
inflammatory changes in synovial tissues of paws from rats
treated from day 14 (Figure 6f). Paw volume increased pro-
gressively in rats without CIA (controls) from day 0 (open cir-
cles in Figure 7a). All arthritic animals groomed themselves
well and maintained original body weight throughout the
course of the disease. Paw volume was significantly greater in
arthritic rats treated with vehicle than in control rats on days 18
and 21 (open squares in Figure 7a; P = 0.038 and 0.007,
respectively). Maximum paw volume was found in rats with CIA
treated with vehicle on day 21 (Figure 7a). Arthritis score was
significantly greater in arthritic rats treated with vehicle than in
control rats on days 18 and 21 (open squares in Figure 7b, P
= 0.007 and 0.001, respectively). The Maximum arthritis score
was found in rats with CIA that were treated with vehicle on
day 28 (Figure 7b).
Effect of anti-IL-23 antibody treatment on joint swelling
Joint swelling in paws was reduced in rats that were treated
with IL-23 blockade from day 14. The 3.0 μg (filled triangles in
Figure 7a) or 6.0 μg (filled diamonds in Figure 7a) dosage of
anti-IL-23 antibody significantly reduced paw volume in rats
treated from day 14 compared with rats treated with vehicle on
day 21 (Figure 7a; P = 0.005 and 0.004, respectively). The
3.0 μg (filled triangles in Figure 7b) or 6.0 μg (filled diamonds
in Figure 7b) dosage of anti-IL-23 antibody reduced the arthri-
tis score in rats treated from day 14 compared with rats
treated with vehicle on day 21 (Figure 7b; P = 0.069 and 0.77,
respectively); however, there were no significant differences
between rat groups.
Effect of anti-IL-23 antibody treatment on joint damage 
as assessed by radiology
Figure 8 shows typical radiographs of left limbs in each group
obtained on day 28. Radiographic joint damage including
bone erosion and loss of joint space was detected in X-rays of
paws of rats with CIA treated with vehicle (Figure 8c,d), but
not from paws of controls (Figure 8a,b). Compared with
arthritic rats treated with vehicle, the 3.0 μg dosage of anti-IL-
23 antibody reduced bone erosion changes and maintained
joint space in arthritic rats treated from day 14 (Figure 8e,f).
Discussion
This is the first report to demonstrate that IL-23 stimulates
human osteoclast differentiation and that neutralizing IL-23
activity after the onset of CIA in rats has therapeutic potential.
Figure 3
IL-23-induced osteoclastogenesis from cultured human peripheral blood mononuclear ell
blood mononuclear cells. A variable concentration of recombinant 
human (rh)IL-23 (0.01, 0.1, or 1 ng/ml) was present during the first 3 
days (days 0 to 4). After 10 days, osteoclasts positive for anti-vitronec-
tin receptor antibody were counted. Data are expressed as means and 
SD for triplicate cultures. Experiments were repeated three times with 
similar, significant results; #P = 0.002 (Student's t test).Page 5 of 12
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human osteoclastogenesis in cultures of PBMC in the
absence of osteoblasts or exogenous sRANKL. We also
investigated whether IL-23 induces osteoclastogenesis from
human monocytes alone; however, rhIL-23 did not do so (data
not shown). In human immune cells, IL-23 receptors are
expressed on activated or memory T cells, on natural killer
cells, and, to a smaller extent, on macrophages and dendritic
cells [9]. We therefore concluded that T cells are important in
IL-23-induced human osteoclastogenesis from PBMC.
To clarify the factors involved in IL-23-induced osteoclas-
togenesis from PBMC, we used various inhibitors such as
OPG (a decoy receptor for RANKL), anti-IL-17 antibody, and
etanercept (a TNF-α blocking agent). All inhibitors clearly sup-
pressed IL-23-induced osteoclastogenesis, even at 1.0 ng/ml,
which was the most effective concentration of IL-23 in
inducing osteoclastogenesis. These results indicate that
cytokines, RANKL [4], IL-17 [21] and TNF-α [22] are, at least
in part, associated with pathogenesis of RA manifested as IL-
23-induced osteoclastogenesis.
To further clarify the mechanism of IL-23-induced osteoclas-
togenesis, we measured two major inflammatory cytokines
that strongly affect osteoclastogenesis, namely IL-17 and IFN-
γ. IL-17 promotes human osteoclastogenesis in vitro via the
RANK–RANKL system or TNF-α [21,22]. We also showed
that IL-17 induces human osteoclastogenesis from human
monocytes even in the absence of osteoblastic cells or
sRANKL through both inductively expressed TNF-α and con-
stitutively expressed RANKL on human monocytes [22]. The
synergistic effect of TNF-α and RANKL is important in this
osteoclastogenesis; each cytokine was present at too low an
expressed level to induce osteoclastogenesis individually [22].
In contrast, IFN-γ strongly inhibits osteoclastogenesis in
humans and mice even at low concentrations [26,28]. We
demonstrated that IL-23 induced IL-17 and IFN-γ production
in human activated T cells, findings in accordance with those
of the previous report by vanden Eijinden and colleagues [11].
Stimulation of T cells in our experiment was, however, much
weaker than reported in that paper: we activated human T cells
by using anti-CD3 antibody (0.1 μg/ml) and anti-CD28 anti-
body (2 μg/ml). In contrast, vanden Eijinden and colleagues
activated human T cells by using anti-CD3 antibody (5 μg/ml)
and anti-CD28 antibody (1 μg/ml), respectively. Our findings
indicate that human T cells activated by mild stimulation can
produce IL-17 and IFN-γ in response to rhIL-23.
Figure 4
Inhibition of IL-23-induced osteoclastogenesis by osteoprotegerin, anti-IL-17 antibody, and etanercepti , ti-I -  ti ,  t r t. Peripheral blood mononuclear cells (PBMC) 
were cultured during the first 3 days with macrophage-colony stimulating factor (M-CSF) and recombinant human (rh)IL-23 (1.0 ng/ml) (c). At the 
same time, osteoprotegerin (OPG, 250 ng/ml) (d), anti-IL-17 antibody (5 μg/ml) (e), or etanercept (0.01 μg/ml) (f) was added with rhIL-23 (1.0 
ng/ml). Adherent cells were cultured with M-CSF alone during the last 7 days (days 4 to 10 (c–f)). As controls, PBMC were cultured with M-CSF 
alone during the first 3 days, after which adherent cells were cultured with M-CSF only (a) (negative control) or with soluble receptor activator of NF-
κB ligand (sRANKL; 100 ng/ml) (b) (positive control). Osteoclasts were detected by immunohistological staining for vitronectin receptor αvβ3 
(CD51/61). Original magnification ×100.Page 6 of 12
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but not IFN-γ production, in a dose-dependent manner from
human activated T cells, although there were no significant
changes in IL-17 production levels by activated T cells after
stimulation with IL-23. Considering the inductive effect of IL-
17 and the inhibitory effect of IFN-γ as described above, how-
ever, we speculate that the balance of these two cytokines is
important. Then we showed that the ratio of production levels
of IL-17 to those of IFN-γ was elevated at 1 to 10 ng/ml IL-23;
it is possible that the higher the ratio of IL-17 to IFN-γ, the
greater the number of osteoclasts induced by IL-23. Although
further studies are needed to clarify the contribution of other
cytokines, for example IL-10 [11], released from T cells acti-
vated by IL-23, our findings suggest that the balance between
IL-17 and IFN-γ may be important in IL-23-induced
osteoclastogenesis.
In the present study, we also showed that IL-23 is important in
inflammation and bone destruction at a later stage, after the
onset of CIA, in rats. Anti-IL-23 antibody administered at the
later stage of clinical arthritis significantly reduced paw volume
in affected rats in a dose-dependent manner. In addition, radi-
ographic and histologic analyses revealed that anti-IL-23 anti-
body tended to inhibit bone destruction in rats with CIA. In
contrast, IL-23 has been reported to be important in the onset
of arthritis in a model using IL-23 (p19)-deficient knockout
mice [16]. In the present study, even at a later stage of CIA in
rats, neutralization of endogenous IL-23 with anti-IL-23
Figure 5
IL-23-induced IL-17 production by activated human T cells in a dose-dependent manner. (a) Human CD3-positive T cells were cultured in the 
absence or presence of recombinant human (rh)IL-23 (1.0 or 3.0 ng/ml). After 48 hours, secretion of IL-17 in the cell culture supernatant was 
assayed by ELISA. Results for one representative donor are presented here and are expressed as means and SD. (b) ELISA measurement of IL-17 
production by human CD3-positive T cells treated for 48 hours with various concentrations of rhIL-23 (1.0, 3.0, or 10 ng/ml) in the presence or 
absence of plate-bound anti-CD3 and anti-CD28, for five representative donors. Data are expressed as means and SD. #P = 0.009 versus non–acti-
vated T cells (Mann–Whitney U test). (c) ELISA measurement of IFN-γ production by human CD3-positive T cells treated for 48 hours with various 
concentrations of rhIL-23 (1.0, 3.0, or 10 ng/ml) in the presence or absence of plate-bound anti-CD3 and anti-CD28, for four representative donors. 
Data are expressed as means and SD. #0.02 versus non–activated T cells (Mann–Whitney U test). (d) Ratio of the production levels of IL-17 to 
those of IFN-γ (IL-17/IFN-γ) calculated from levels of IL-17 or IFN-γ produced from activated CD3-positive T cells at each concentration of rhIL-23 (0, 
1, 3, or 10 ng/ml).Page 7 of 12
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Variation in degree of inflammation of rat paws after treatment with vehicle or IL-23 blockade. (a–c) Photographs showing paws of rats with colla-
gen-induced arthritis (CIA) that were treated with vehicle or anti-IL-23 antibody on day 21. (a) Control rats. (b) Rats with CIA that were treated with 
vehicle. (c) Rats with CIA that were treated with anti-IL-23 antibody (3.0 μg) from day 14. (d–f) Slides stained with hematoxylin and eosin represent-
ing synovial tissues obtained from right paws on day 28. (d) Control rats. (e) Rats with CIA that were treated with vehicle. (f) Rats with CIA that 
were treated with anti-IL-23 antibody (3.0 μg) from day 14. Original magnification ×100.
Figure 7
Variation in paw volume in rats with CIA treated with vehicle or IL-23 blockade. (a) Paw volumes of control rats, vehicle-treated rats with collagen-
induced arthritis (CIA), and rats with CIA that were treated with anti-IL-23 antibody, from day 0 to day 21. Open squares, rats with CIA treated with 
vehicle; open circles, controls; filled triangles, rats with CIA treated with 3.0 μg of anti-IL-23 antibody; filled diamonds, rats with CIA treated with 6.0 
μg of anti-IL-23 antibody. Means ± SD are shown. #P = 0.021 versus controls, ##P = 0.021 versus controls, ¶P = 0.014 versus vehicle, §P = 0.007 
versus vehicle (Mann–Whitney U test). (b) Arthritis scores of control rats, vehicle-treated rats with CIA, and rats with CIA that were treated with anti-
IL-23 antibody, from day 0 to day 28. Open squares, rats with CIA treated with vehicle; open circles, controls; filled triangles, rats with CIA treated 
with 3.0 μg of anti-IL-23 antibody; filled diamonds, rats with CIA treated with 6.0 μg of anti-IL-23 antibody. Means ± SD are shown. #P = 0.021 ver-
sus controls, ##P = 0.021 versus controls (Mann–Whitney U test).Page 8 of 12
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destruction, indicating that IL-23 is necessary to induce
inflammation and osteoclastogenesis even after the onset of
clinical arthritis.
Staining of synovial tissues with hematoxylin and eosin
showed that treatment with a low dose (3.0 μg) of anti-IL-23
antibody markedly reduced inflammatory changes and carti-
lage and bone destruction in paws, in contrast with findings in
rats treated with vehicle. The 3.0 μg or 6.0 μg dosage of anti-
IL-23 antibody reduced arthritis score in rats treated from day
14; however, there were no significant changes between rats
treated with vehicle and those treated with anti-IL-23 antibody.
The reason for these findings is unclear but may be related to
the small number of rats used in this study. With regard to
arthritis score, the effect of treatment with a high dose (6.0 μg)
of anti-IL-23 antibody was smaller than that of treatment with
a low dose (3.0 μg) of anti-IL-23 antibody. We speculate that
antibodies against anti-IL-23 antibody might be produced in
rats. In other words, a low dose of anti-IL-23 antibody may not
induce the production of antibodies against anti-IL-23
antibody.
In this study, radiographic analyses revealed that treatment
with anti-IL-23 antibody after the onset of CIA inhibited the
progression of X-ray changes including joint space narrowing
and bone erosion. A previous report revealed that expression
of proinflammatory cytokines including TNF-α, IL-1β, and IL-6
is markedly reduced in IL-23-deficient (IL-23 p19-/-) mice [16].
These cytokines promote bone resorption by inducing differ-
entiation of osteoclasts [2,6,7]. These findings therefore sug-
gest that in vivo blockade of endogenous IL-23 has an effect
on preventing bone destruction through a decrease in inflam-
matory cytokines associated with bone destruction. Taken
together, our findings also indicate that anti-IL-23 antibody
could reduce not only inflammation but also bone destruction.
The in vivo function of IL-23 remains to be determined; how-
ever, recent reports show that IL-23 stimulation can lead to the
generation of an alternative T helper cell subset characterized
by expression of high levels of the proinflammatory cytokine IL-
17, but only low amounts of IFN-γ [10,11,16,18,29,30]. This
novel T cell population was described as 'THIL-17.' A recent
report by Langrish and colleagues [18] emphasizes the role of
THIL-17 cells in an animal model of EAE. In this report, the
Figure 8
Typical radiographic images obtained on day 28, showing differences in paws. The groups were control rats, vehicle-treated rats with collagen-
induced arthritis (CIA), and rats with CIA treated with anti-IL-23 antibody on day 28. (a, c, e) Frontal views; (b, d, f) lateral views. (a, b) Control rats. 
(c, d) Rats with CIA treated with vehicle. (e, f) Rats with CIA treated with anti-IL-23 antibody (3.0 μg) from day 14. Note that rats wth CIA treated 
with vehicle showed radiographic changes characterized by bone erosion and joint space narrowing.Page 9 of 12
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autoimmune inflammation in the brain and the neutralization of
soluble IL-17 by using antibodies that partly protected the
experimental mice from EAE. In the animal model of CIA, the
resistance of IL-23 knockout mice was found to depend on the
absence of IL-17-producing T helper cells, but not on an
impaired Th1 immune response, demonstrating again the pos-
sible role of THIL-17 cells in chronic and autoimmune inflamma-
tion [16]. A possible explanation for the effect of anti-IL-23
antibody on CIA is therefore that the number of IL-17-produc-
ing T cells might be reduced by IL-23 blockade.
In contrast, it has been shown with the use of an EAE model
that adoptive transfer of IL-23-induced, IL-17-producing
effector cells induces disease, whereas IL-12-induced, IFN-γ-
producing effector cells do not [18]. Moreover, treatment with
anti-IL-17 reduced disease severity in this study, whereas
treatment with anti-IFN-γ exacerbated disease. Similarly, stud-
ies with IFN-γ-deficient and IFN-γ R-deficient mice have shown
that IFN-γ and Th1 cells are not necessary for the development
of autoimmunity in both EAE and CIA [31,32]. Furthermore,
Park and colleagues recently reported that IFN-γ, IL-12, and IL-
4 strongly inhibit the generation and population expansion of
IL-17-expressing cells and their cytokine expression [33].
These studies suggest that at least IFN-γ may actually have a
protective function. Thus, in view of the protective function of
IFN-γ, the effect of anti-IL-23 antibody in our model of CIA may
have been to normalize the ratio of IL-17 to IFN-γ; the IL-17
level was decreased, whereas that of IFN-γ did not change.
In our in vitro study, we showed that IL-23 induced key
cytokines such as IL-17 and IFN-γ and that IL-23 induced
human osteoclastogenesis via these cytokines (Figure 9). Our
findings indicate that loss of the IL-17/IFN-γ balance leads to
enhanced osteoclastogenesis induced by IL-23. Moreover, we
speculate that IL-17, produced by T cells stimulated with IL-
23, acts on monocytes, resulting in TNF-α production and
inducing the differentiation of monocytes into mature osteo-
clasts through interaction with RANKL. In addition, the RANK–
RANKL pathway expressed on monocytes induces osteoclast
differentiation by binding to RANK. It has been reported that
the gene expression of TNF-α is enhanced in synovial tissue of
patients with RA [34] and that TNF-α accumulates in synovial
fluids from patients with RA [35]. In addition, we and other
groups have detected RANKL in synovial tissue and fluids
from patients with RA [3,36,37]. From a clinical point of view,
we believe that the levels of IL-17 induced by IL-23 in our
experiment would significantly affect osteoclastogenesis in
patients with RA because the concentrations of IL-17 in syno-
vial fluid and culture medium of synovial tissue obtained from
patients were less than 14 pg/ml and 40 pg/ml, respectively,
in a previous study [21]. Thus, beginning with IL-23, the com-
bined effects of TNF-α, RANKL, and IL-17 levels, all of which
are elevated in patients with RA, contribute to osteoclastic
bone resorption.
Figure 9
Mechanism of effect of IL-23 on human osteoclastogenesis. In a culture of human peripheral blood mononuclear cells, IL-23 directly induced osteo-
clastogenesis even in the absence of exogenous soluble receptor activator of NF-κB ligand (sRANKL). IL-17 induced by IL-23 from human activated 
T cells is the crucial cytokine for osteoclastogenesis through the mechanism of the RANK–RANKL system and TNF-α; IL-17 acts on monocytes, 
resulting in TNF-α production, inducing the differentiation of monocytes into osteoclasts by cooperating with RANKL, although RANKL alone 
expressed on monocytes does not induce osteoclastogenesis by binding to RANK. Furthermore, considering the inductive effect of IL-17 and the 
inhibitory effect of IFN-γ, it is speculated that the higher the ratio of IL-17 to IFN-γ, the greater the number of osteoclasts induced by IL-23. Ab, anti-
body; OPG, osteoprotegerin.Page 10 of 12
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In the present experiments, IL-23 directly induced osteoclas-
togenesis in cultures of human PBMC. Our findings strongly
suggest that IL-23 is important in joint inflammation and bone
destruction during the effector phase of CIA via the IL-23–IL-
17 pathway and that IL-23 is an attractive target for the treat-
ment of destructive arthritis. Furthermore, controlling the
expression of IL-23 in patients with RA may provide a new
treatment for inhibition of inflammation and bone destruction.
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